Mediscience Technology Corp. OTC-MDSC Secures Exclusive World-Wide License to US Molecular Imaging Patent Applications, Expected to Extend Core Technology Additional 17+ Years.

Business Editors/Health/Medical Writers

BIOWIRE2K

CHERRY HILL, N.J.--(BUSINESS WIRE)--Dec. 3, 2003

Mediscience Technology Corp. (MTC), (OTCBB:MDSC) of Cherry Hill, New Jersey, a developer of imaging technology for molecular detection of cancer and physiological change, announced its contractual acquisition of two exclusive world-wide licenses for US patent applications filed by The Research Foundation City University of New York (RFCUNY). 1. "Stokes-Shift Fluorescence spectroscopy for detection of disease and physiological state of specimen" and 2. "Three-dimensional Radiative Transfer Tomography for Turbid Media." The work results from the Company's continual 10-year+ University research funding relationship. President and Chief Operating Officer Michael Engelhart and CUNY inventor Dr. Robert Alfano state that "the patents, when issued, would extend the Company's core technology in Optical Biopsy for an additional 17+ years, thus expanding, maintaining and continuing our IP leadership in the Optical Biopsy field."

NOTE: SEE: Mediscience SEC/EDGAR 8-k filing dated: December 3, 2003

Web Page: MEDISCIENCETECH.com See (IEEE Journal of selected topics in Quantum Electronics March-April 2003 Vol. 9 Dr. Alfano page 148 and page 189.

INVESTOR NOTICE:

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.